Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Salicylic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 4/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salicylic Acid SCHEMBL31344155 | 1.00 | GRM5 (0.40) | GRM5CHRNB2CHRNB4CHRNA3CHRNA7 | |
| Benzoic Acid SCHEMBL27199922 | 0.87 | CHRNB2 (0.43) | GRM5CHRNB2CHRNB4CHRNA3CHRNA7 | |
| Acetic Acid SCHEMBL27199873 | 0.84 | GRM5 (0.44) | GRM5CHRNB2CHRNB4CHRNA3CHRNA7 | |
| Salicylic Acid SCHEMBL27199866 | 0.84 | BLM (0.46) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| Salicylic Acid SCHEMBL31344158 | 0.84 | BLM (0.46) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| Salicylic Acid SCHEMBL27199836 | 0.84 | AADAT (0.42) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| Salicylic Acid SCHEMBL31344154 | 0.84 | AADAT (0.42) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| Salicylic Acid SCHEMBL31344273 | 0.82 | KDM4E (0.41) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| Salicylic Acid SCHEMBL27199863 | 0.82 | KDM4E (0.41) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL30866543 | 0.81 | CHRNB2 (0.49) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4683527-A1 | VAPORIZABLE ALKALOID COMPOSITIONS AND METHODS OF USE THEREOF | Ready Mix Naturals, LLC (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20250289796-A1 | COMPOSITIONS AND METHODS OF USE THEREOF | Ready Mix Naturals, LLC (US) | 2025-09-18 | — | — | US | disclosed |
| US-12358889-B2 | Vaporizable alkaloid compositions and methods of use thereof | Ready Mix Naturals, LLC (US) | 2025-07-15 | — | — | US | disclosed |
| US-12358888-B2 | Vaporizable alkaloid compositions and methods of use thereof | Ready Mix Naturals, LLC (US) | 2025-07-15 | — | — | US | disclosed |
| WO-2024155297-A1 | VAPORIZABLE ALKALOID COMPOSITIONS AND METHODS OF USE THEREOF | Ready Mix Naturals, LLC (US) | 2024-07-25 | — | — | WO | disclosed |
| US-20240246930-A1 | VAPORIZABLE ALKALOID COMPOSITIONS AND METHODS OF USE THEREOF | Ready Mix Naturals, LLC (US) | 2024-07-25 | — | — | US | disclosed |
| US-11964958-B1 | Vaporizable alkaloid compositions and methods of use thereof | Ready Mix Naturals, LLC (US) | 2024-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246930-A1 | VAPORIZABLE ALKALOID COMPOSITIONS AND METHODS OF USE THEREOF | SRM, SCLY, SMOX | GRM5 577/4885CHRNB2 98/4885CHRNB4 55/4885 |
| US-11964958-B1 | Vaporizable alkaloid compositions and methods of use thereof | SRM, SCLY, SMOX | GRM5 577/4885CHRNB2 98/4885CHRNB4 55/4885 |
| US-20250289796-A1 | COMPOSITIONS AND METHODS OF USE THEREOF | OR10J3, TRPA1, TAS2R3 | GRM5 90/4885CHRNB2 389/4885CHRNB4 205/4885 |
| US-12358888-B2 | Vaporizable alkaloid compositions and methods of use thereof | SRM, SCLY, SMOX | GRM5 577/4885CHRNB2 98/4885CHRNB4 55/4885 |
| US-12358889-B2 | Vaporizable alkaloid compositions and methods of use thereof | SRM, SCLY, SMOX | GRM5 577/4885CHRNB2 98/4885CHRNB4 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.